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Abstract. It is well recognized that arsenic trioxide (ATO) is an efficacious agent
of acute promyelocytic leukemia (APL). Use of single agent ATO in the treatment of APL leads to 
remissions which are durable in the majority. ATO is probably the most effective single agent in the 
treatment of APL and there have been ver
both as a single agent and in combination with other conventional drugs to treat APL. Use of ATO 
is  the  accepted  standard  of  care  in  the  management  of  relapsed  APL,  where  it  is  often  used 
effectively as a bridge to a stem cell transplant. However, its role in newly diagnosed APL remains 
controversial.  ATO  probably  has  multiple  mechanisms  of  action.  Better  understanding  of  its 
mechanisms of action/s is likely to lead to more rationale use of this agent or
alone  or  in  combination  with  other  drugs.  There  is  limited  data  on  the  kinetics  of  leukemia 
clearance and normal haematopoietic recovery after the administration of single agent ATO for the 
treatment of  APL, preliminary data  suggest
therapy. There have been a number of concerns of the potential short and long term toxicity of this 
agent. Most such concerns arise from the toxicity profile noted in people exposed to long term 
arsenic exposure in the environment. With the therapeutic doses and schedules of administration of 
ATO in the treatment of malignancies the overall toxicity profile has been favorable. In a resource 
constrained environments the use of a single agent ATO based reg
option to treat almost all patients. In the developed world it has the potential in combination with 
other agents to improve the clinical outcome with reduction of dose intensity of chemotherapy and 
remains an option for patients who would not tolerate conventional therapy. In this review we focus 
on the use of single agent ATO for the treatment of APL and summarize our experience and review 
the literature.
Introduction. Arsenical compounds were used as early 
as 2000 BC, both as a medicine and as a poison
use of these compounds as medicines was familiar to 
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It is well recognized that arsenic trioxide (ATO) is an efficacious agent
of acute promyelocytic leukemia (APL). Use of single agent ATO in the treatment of APL leads to 
remissions which are durable in the majority. ATO is probably the most effective single agent in the 
treatment of APL and there have been very few reports of primary resistance. It has been used 
both as a single agent and in combination with other conventional drugs to treat APL. Use of ATO 
is  the  accepted  standard  of  care  in  the  management  of  relapsed  APL,  where  it  is  often  used 
a bridge to a stem cell transplant. However, its role in newly diagnosed APL remains 
controversial.  ATO  probably  has  multiple  mechanisms  of  action.  Better  understanding  of  its 
mechanisms of action/s is likely to lead to more rationale use of this agent or
alone  or  in  combination  with  other  drugs.  There  is  limited  data  on  the  kinetics  of  leukemia 
clearance and normal haematopoietic recovery after the administration of single agent ATO for the 
treatment of  APL, preliminary data  suggests  that it is  likely  to be  different from conventional 
therapy. There have been a number of concerns of the potential short and long term toxicity of this 
agent. Most such concerns arise from the toxicity profile noted in people exposed to long term 
exposure in the environment. With the therapeutic doses and schedules of administration of 
ATO in the treatment of malignancies the overall toxicity profile has been favorable. In a resource 
constrained environments the use of a single agent ATO based regimen is a realistic and acceptable 
option to treat almost all patients. In the developed world it has the potential in combination with 
other agents to improve the clinical outcome with reduction of dose intensity of chemotherapy and 
patients who would not tolerate conventional therapy. In this review we focus 
on the use of single agent ATO for the treatment of APL and summarize our experience and review 
Arsenical compounds were used as early 
as 2000 BC, both as a medicine and as a poison
1. The 
use of these compounds as medicines was familiar to 
the early physicians such as Hippocrates (460 
BC), Aristotle (384 – 322 BC) and Pliny the Elder (23 
– 79 AD). It was Paracelsus (1493 
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It is well recognized that arsenic trioxide (ATO) is an efficacious agent for the treatment 
of acute promyelocytic leukemia (APL). Use of single agent ATO in the treatment of APL leads to 
remissions which are durable in the majority. ATO is probably the most effective single agent in the 
y few reports of primary resistance. It has been used 
both as a single agent and in combination with other conventional drugs to treat APL. Use of ATO 
is  the  accepted  standard  of  care  in  the  management  of  relapsed  APL,  where  it  is  often  used 
a bridge to a stem cell transplant. However, its role in newly diagnosed APL remains 
controversial.  ATO  probably  has  multiple  mechanisms  of  action.  Better  understanding  of  its 
mechanisms of action/s is likely to lead to more rationale use of this agent or its derivatives either 
alone  or  in  combination  with  other  drugs.  There  is  limited  data  on  the  kinetics  of  leukemia 
clearance and normal haematopoietic recovery after the administration of single agent ATO for the 
s  that it is  likely  to be  different from conventional 
therapy. There have been a number of concerns of the potential short and long term toxicity of this 
agent. Most such concerns arise from the toxicity profile noted in people exposed to long term 
exposure in the environment. With the therapeutic doses and schedules of administration of 
ATO in the treatment of malignancies the overall toxicity profile has been favorable. In a resource 
imen is a realistic and acceptable 
option to treat almost all patients. In the developed world it has the potential in combination with 
other agents to improve the clinical outcome with reduction of dose intensity of chemotherapy and 
patients who would not tolerate conventional therapy. In this review we focus 
on the use of single agent ATO for the treatment of APL and summarize our experience and review 
the early physicians such as Hippocrates (460 – 377 
322 BC) and Pliny the Elder (23 
79 AD). It was Paracelsus (1493 – 1541 AD) who Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
used arsenicals extensively and was quoted as saying 
“All  substances  are  poisons;  the  right  dose 
differentiates  a  poison  from  a  remedy”.
1 In  the 
eighteenth  century,  Fowlers  solution  (1%  potassium 
arsenite)  was  very  popular  and  was  used  in  the 
treatment  of  various  ailments,  predominantly  for 
dermatological conditions.
1
Historically  the  prominence  of  arsenic  trioxide 
(ATO)  in  the  treatment  of  acute  promyelocytic 
leukemia (APL) followed the observation of Chinese 
investigators  at  Harbin  Medical  University  who 
systematically  studied  the  role  of  arsenic  based 
traditional  Chinese  recipe  called  ‘Ailing  I,’  that  had 
been reported to be useful in the treatment of various 
malignancies.  They labeled this native preparation 713 
(for the year and month that the study was initiated) 
and studied it more than a 1000 patients with various 
malignancies
2. They soon noted that this agent worked 
best  in  the  treatment  of  patients  with  APL.  Two 
subsequent  Chinese  studies  confirmed  the  benefit  of 
this agent in APL.
3,4
Since then there have been numerous reports on the 
use  of  ATO  in  the  treatment  of  relapsed  and  newly 
diagnosed  cases  of APL.  In  this  review  we  focus 
mainly  on  the  treatment  of  APL  with  single  agent 
ATO. We review our centers experience from 1998 and 
attempt to put this into context of current international 
management strategies, experience from other centers 
and  address  the  socio-economic  relevance  of  this 
strategy. We also attempt to highlight the significant 
differences  in  this  approach  compared  to  that  when 
chemotherapeutic  agents  are  used  up  front.  Very 
briefly we also address the mechanism of action of this 
agent,  the  pharmacokinetic  data  and  toxicity  profile 
which we feel is critical to this discussion.   
Mechanism  of  Action  of  Arsenic  Trioxide.  The 
mechanism by which ATO induces remission in APL 
is  still  under  evaluation.  Table  1 summarizes  the 
postulated  mechanisms by  which  ATO  mediates  its 
anti-leukemia effect. While some aspects of its cellular 
effects are clear, the molecular basis, for these protean 
effects  are  not  fully  defined.  Initial  in-vitro  studies 
suggested that it induces apoptosis in APL (NB4) cell 
lines  by  down  regulation  of  Bcl-2.
5 However,  the 
clinical observation that a leucocytic response followed 
the administration of ATO consistently in the majority 
of patients, was suggestive of a differentiating process, 
as  seen  following  the  use  of  all-trans  retinoic  acid 
(ATRA).  It  was  subsequently  reported  that  in  fact  a 
dual  effect  of  ATO was  seen  on  promyelocytic  cell 
lines, at low doses (0.1 – 0.5  umol/lt) there was partial 
differentiation  and  at  higher  doses  there  was 
preferential apoptosis (0.5 – 2 umol/lt).
6 This has been 
subsequently  demonstrated by  a  number  of other
Table 1. Mechanism of action of arsenic trioxide.
I] Induce apoptosis
(0.5-1.0µM)
II] Induce differentiation
( <0.5µM)
-downregulation of bcl2
5 -degradation of PML-RARα
57
-increased expression of 
caspases
58 - methylation of histones
59
-activation of jun kinases
60
-reorganize PML oncogenic 
domain (POD)
61,62
-disruption of cytoskeleton
63
-inhibition of NFkB
64,65
III] Altered cellular Redox 
status IV] Inhibits angiogenesis
-reactive oxygen species (ROS) 
generation67,68 -down regulates VEGF
66
-bind sulfhydryl rich 
proteins/enzymes such as 
glutathione and reduce there 
levels69 
groups independently.
7,8The differentiation with ATO 
is  incomplete  and usually  proceeds  only  till  the 
myelocyte  stage  following  which  it  appears  that 
apoptosis  is  the  predominant  mode  of  action.
6 More 
recently  data  suggests  that  ATO  but  not  ATRA  can 
eliminate  the  leukemia  initiating  compartment  in 
APL.
9,10 This could partly explain why ATO but not 
ATRA,  as  single  agent,  is  able  to  induce  durable 
remission in the clinic.
Pharmacokinetics,  Pharmacogenomics,  Dose  and 
Schedule  of  Arsenic  Trioxide.  The  lethal  dose 
recorded in the literature is a single dose of more than 
100mg
11. The  dose  of  arsenic  trioxide  in  the  initial 
published study by Zhi-Xiang et al
11 was 10 mg a day 
for adults till complete hematological remission (CR) 
was  achieved. Subsequently  a  break  of  30  days was 
given and a second course of 28 days administered. It 
is important to recognize that this dosing was based on 
there  earlier  experience  with  doses  used  in  native 
Chinese  medicine  and  not  on  phase  I  clinical  trials 
addressing dose limiting toxicity. The study reported 
by Soignet et al
12 used a similar dose for adults but 
used a dose of 0.15 mg/kg/day for children. From there 
experience they noted that ATO is active in APL from 
0.06mg/kg to 0.2 mg/kg. Within this range they did not 
find  any  difference  in  efficacy.  Subsequent  studies 
have  used  similar  dosages  of  ATO.  Pharmacokinetic 
studies  done  at  this  dosage  demonstrated  that  mean 
peak plasma levels of 6.85 micro moles / Lt (range: 
5.54 – 7.30) was achieved. The plasma half life was 
12.13±3.31 hours. Importantly these parameters did not 
change  with  continuous  administration.
11 Reports  of 
daily  urinary  excretion  in  the  literature  varies  from 
between  1  – 8%  to  32-65%  of  the  daily  dose 
administered and more importantly is continued even 
after  the  drug  administration  had  been  stopped.
11,13Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
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There  is  limited data  on  the  dose  and  scheduling  of 
ATO  in  the  event  of  significant  renal  failure  or  for 
patients  on  dialysis.
14 While  the  cumulative  level  of 
arsenic increases in the body (as demonstrated in hair 
and nail analysis) with continuous administration, the 
urinary  excretion  continues  even  after  the  ATO 
administration  has  stopped  leading  to  a  gradual 
decrease in the cumulative amount of arsenic trioxide 
in  the  body.  In  our  own  experience  there  was  no 
significant difference in the ATO content from patients 
and normal controls hair and nail samples on long term 
follow up.
15 This was the rationale for giving 4 week 
breaks  between  the  courses  of  ATO  in  the  regimen 
used by us,
16 the breaks were intended to reduce the 
cumulative dose significantly. 
This pattern of ATO exposure is very different from 
that seen with environmental toxicity where there is a 
slow but constant accumulation of arsenic which leads 
to a toxicity profile that is very different from that seen 
when  ATO is  used  in  therapy  at  currently 
recommended doses and schedules. Extrapolating and 
anticipating  the  toxicity  profile  seen  with  chronic 
environmental exposure to the potential toxicity with 
currently  used  dosage  schedules  of  ATO  is  unfair, 
unwarranted  and  without  any  scientific  basis.  In  the 
absence of a dose defining phase I clinical trial there is 
insufficient data on the upper limit of a safe therapeutic 
dose. It is of interest to note that in our initial cohort we 
noted a decreased risk of relapse among patient who 
had  hepatotoxicity  Vs.  those  that  did  not  following 
treatment with ATO
17 (Figure 1). This would suggest 
that  there  is  either  a  significant  inter-individual 
variation in  biotransformation  of this agent  and as a 
result  some  patients  were  receiving  less  than  an 
optimal dose or that there were yet unknown variables 
that resulted in this association.
17 There is a need to 
revisit what is the optimal dose of ATO to treat APL in 
a large clinical trial. There is very limited data on the 
optimal duration of administration of ATO as a single 
agent in the management of ATO. Based on the general 
consensus  that  maintenance  was  required  in  the 
management  of  APL  we  arbitrarily  opted  for  a  6 
months duration of maintenance.
16 Recently published 
data  from  Iran  suggests  that  4  courses  of  ATO  was 
significantly  better  than  2.
18 We  subsequently 
undertook a larger multi-center study and randomized 
patients with the same induction and consolidation into 
a 6 and a 12 month maintenance regimen and did not 
find a significant benefit from increasing the duration 
of maintenance (unpublished data, to be presented at 
ASH 2011). Zhou et al reported treating children with 
ATO for prolonged periods of up to 3 years with very 
good efficacy and without significantly increasing the 
toxicity.
19   
It has been noted that there is considerable inter 
Figure 1. Five year Kaplan-Meier product limit estimate of disease 
free survival in the group that had hepatotoxicity, n=23 and those 
that did not, n=39. 
individual variation in susceptibility to ATO induced 
toxicity, which is probably related to differences in in-
vivo biotransformation of arsenic. This in turn could be 
a result of age, nutritional status, co-morbid conditions, 
environmental factors and genetic polymorphisms.
20 In 
addition  to  a  poorly  characterized  arsenic 
methyltransferase, a number of other enzyme systems 
and polymorphisms have been shown to have an effect 
on arsenic methylation.
20,21 Of these, polymorphism in 
the  methylene  tetra-hydrofolate  reductase  (MTHFR) 
gene, which results in MTHFR deficiency in 10-20% 
of the Caucasian population, has been reported to be 
associated  with  increased  arsenic  related 
neurotoxicity.
22 The  glutathione  S-transferases  (GST) 
are  a  family  of  proteins  that  conjugate  glutathione 
(GSH) to various electrophiles.
23 Chiou et al reported 
that genetic polymorphisms of GST M1 and GST T1 
altered the methylation of arsenic.
24 GST’s catalyze the 
GSH dependent  reduction of  hydroperoxides to  their 
corresponding  alcohols and  help  prevent propagation 
of  free  radicals.  It  is  conceivable  that  genetic 
polymorphisms  in  these  genes  could  alter  the 
biotransformation of ATO, which in turn could have an 
impact on the efficacy and toxicity profile of this drug. 
We had earlier reported that the hepatotoxicity profile 
in  a  cohort  of  patients  with  newly  diagnosed  APL 
treated at our center with a single agent ATO regimen 
was  significantly  associated  with  the  homozygous 
mutant  of  MTHFR  1298  (C/C)  (RR=8.75,  p=0.004) 
and  there  was  a  trend  towards  an  increased  risk  of 
hepatotoxicity  associated  with  the  GST  M1  null 
genotype (RR=3.28, p=0.06).
17 We had hypothesized 
then that alteration in biotransformation possibly leads 
to  quantitative  and  qualitative  differences  in  the 
methylated  intermediaries  that  are  generated;  these 
differences could have a bearing on the efficacy and 
toxicity  profile  of  ATO.  A  recent  study,  in  part, Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
validates  this  hypothesis by  suggesting  that 
dimethylarsinous  acid  is  more  toxic  than  inorganic 
ATO and monomethylyarsinic acid,
25 these are some of 
the  methylated  intermediaries  produced  in-vivo  in 
humans  and  animals.  It  is  potentially  possible  to 
consider in future the use of pure or combination of 
methylated ATO derivatives with optimal therapeutic 
and toxicity profiles. 
Clinical Experience with the Use Of  Single Agent 
Arsenic Trioxide in Acute Promyelocytic Leukemia. 
The earliest clinical data available on the use of arsenic 
trioxide  in  the  treatment  of  acute  promyelocytic 
leukemia is from two publications from  China.
26,27 In 
these studies the complete hematological remission rate 
(CR)  achieved  varied  from  65.6%  to  84%  and  long 
term survival (>10 years) was seen in 9/32 patients in 
one  of  these  studies.
11 Majority  of  the  early  trials 
involved relapsed cases of APL. There is limited data 
on the use of this as a single agent in the management 
of newly diagnosed cases of APL. Even when used as a 
single  agent  for  induction  chemotherapy  the 
subsequent  consolidation  therapy  varies  making 
comparisons  between  the  published  data  difficult  to 
interpret. 
Our  early  experience  with  ATO  consisted  of  two 
patients who were treated in the early 1990’s with what 
was  then  considered  standard  of  care  regimens,  one 
with  ATRA  and  one  without.  Both  these  patients 
relapsed and were sent on palliative care considering 
the therapeutic options were limited, that the options 
were  associated  with  poor  clinical  outcome  and  that 
they were very expensive. These patients subsequently 
took treatment  from an ayurvedic (indigenous Indian 
medicine)  practitioner  and  went  into  durable 
remissions. We were aware that the agent used by the 
practitioner  contained  ATO.  We  were  however,  not 
sure of the dose used. The therapeutic ayurvedic mix 
was administered continuously in these cases and for 
more than 5 years in one case. One of these patients 
developed  severe  arsenic  keratosis  and  died  of  a 
secondary squamous epithelial carcinoma.
28
It was only after the publication in 1997 by Shen et 
al that we had a sense of the dose of pure ATO that 
could  be  used  in  humans.
11 In  1998,  we  initiated  a 
study  using  single  agent  ATO  to  treat  APL,  with 
intravenous ATO being manufactured in house in our 
hospital  pharmacy  (the  basic  cost  without  overheads 
per 10mg vial was Indian Rupees 20 or approximately 
US  50  cents),  with  appropriate  quality  control 
measures.  Due  to  legal  related  issues  we  transferred 
this  manufacturing  process  to  the  industry  in  2001 
(INTAS pharmaceuticals Ltd, Matoda, Gujarat, India). 
Our  observation  was  that  there  was  no  significant 
difference  with  the  agent  prepared  by  us  or  that 
subsequently  manufactured  by  industry  in  terms  of 
infusion related toxicity or efficacy (unpublished data).      
From January 1998 to  December  2004, 72 newly 
diagnosed cases of APL were treated with a regimen of 
single  agent  ATO  at  our  center.  The  details  of  the 
regimen  were  as  previously  reported.
15,16 Overall  62 
(86.1%) achieved a hematological remission (CR). A 
total of 13 patients relapsed. At a median follow up 60 
months, the 5 year Kaplan-Meier estimate of EFS, DFS 
and  OS  was  69±5.5%,  80±5.2%  and  74.2±5.2% 
respectively  (Figure  2).  This  data  has  since  been 
validated  by  a  subsequent  multi-center  trial  in  India 
involving  7  centers  across  the  country  (unpublished 
data to be presented at ASH 2011). The data from other 
major studies using either single agent ATO or a ATO 
as a major component in front line therapy
18,19,29-31 is 
summarized in table 2.
Table 2: Summary of studies using arsenic trioxide in front line 
therapy in the treatment of APL.
N CR EFS/DFS
Mathews et al.
15 72 86%
5 year EFS 69%
5 year OS 74%
Ghavamzadeh et 
al.
18 197 86%
5 year OS 64%
5 year DFS 67%
Hu et al.
31
85 94%
5 year EFS 89%
(+ATRA
*+chemo) 5 year OS 92%
Ravandi et al.
29
82 91% 3 year OS 85%
(+ATRA, +GO
#) 
Niu et al.
37 11 73% 1 year OS 73%
Powell et al.
70
244 NA
@ 3 year EFS 80%
(RCT
$ ATO post 
induction) 3 year OS 86%
Gore et al.
30 45 NA 3 year EFS 76%
(ATO post induction) 3 year OS 88%
* ATRA  – all-trans retinoic acid. # GO – gemtuzumab. @ NA  –
not applicable. $ RCT  – randomized controlled trial. 
Toxicity Profile of Arsenic Trioxide. the Theoretical 
Hysteria  Versus  the  Actual  Reality! The  toxicity 
profile in the initial series reported by us was mild, in 
the  majority.
16 Significantly,  there  were  no  infusion 
related toxicities, alopecia or evidence of exacerbation 
of coagulopathy. Post induction, almost all patients for 
the  rest  of  the  duration  of  treatment  had  ECOG 
performance scores of 0 or 1. The non hematological 
toxicities,  as  reported  earlier,
16 in  the  majority  were 
mild, frequently reverted on continuing ATO and in the 
rest were reversible on discontinuing the drug for an 
interval  of  1  – 2  weeks.
16 As  reported  previously  5 
(6.9%)  cases  developed  a  differentiation  syndrome 
which resolved in 4 and was fatal in one. There were Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 2. Five year Kaplan-Meier product limit estimate of (A) Overall survival of (n=72) (B) Event free survival (n=72).
no sudden deaths attributable to a cardiac event in this 
series  of  patients  and  on  long  term  follow  up  there 
were no cases with clinical cardiac dysfunction. There 
were no documented second malignancies documented 
in this cohort.
15 Post remission induction, this regimen, 
was  administered  on  an  out  patient  basis.  With  the 
exception of  some  early  reports  of increased  hepatic 
and  cardiac  toxicity
32-35 the  majority  of  subsequent 
reports using ATO in newly diagnosed cases is similar 
to our experience.
18,19,29-31
There have been periodical major concerns raised 
about the administration of ATO. Very early there was 
a  concern  about  cardiac  arrhythmia  related  sudden 
deaths  in  patients  with  APL  who  were  treated  with 
ATO. Almost all these deaths happened in induction in 
previously  heavily  treated  patients.
32-34 There  have 
been no such deaths reported when ATO was used for 
treating a number of other malignancies, albeit stable 
patients.  Similarly,  it  does  not  appear  when 
administered  to  patients  with  APL  who  are  in 
remission (none reported in the literature).  The role of 
QTc  interval  prolongation  and  limitations  of  the 
corrected  QTc  interval  value  generated  with 
tachycardia  due to  any cause  such  as  infection  have 
been  reviewed  previously  and  it  increasingly 
recognized and accepted that QTc prolongation is an 
electrocardiographic  phenomenon  with  little  clinical 
significance in the majority of patients.
36 This does not 
mean  we  should  not  monitor  it  or  ignore  it,  though 
response should be judicious and clinically appropriate. 
It  has  been  reported  that  in  more  than  2900  cases 
treated by US-FDA approved ATO there have been no 
arrhythmia  related  deaths.
36 We  do  not  believe  that 
there is anything sacrosanct or superior about the US-
FDA approved ATO but rather that it in reality it was 
never a significant clinical problem beyond a few case 
reports where the arrythmia’s were probably related to 
other etiologies or at least in part contributed by them.
Next was the suggestion of acute hepatic failure and 
death from hepatoxocity occurred with ATO.
37 There 
have been  no  other  major  reports  since  this  initial 
publication about 12 years ago. This has definitely not 
been  our  experience  with  more  than  250  patients 
treated  to  date  at  our  center  (newly  diagnosed  and 
relapsed). 
There  has  always  been  a  concern  of  second
malignancies with the use of ATO. This is based on in-
vitro experiments suggesting oxidative DNA damage
38
and  clinical  observations  from  cases  with  long  term 
environmental exposure. This theoretical concern is in 
contrast to clinical data available. In early reports of 
investigators from China it was noted that there was no 
increase in second malignancies in patients followed up 
for  10  years.
11 A  similar  observation  was  made  in 
1982, in a cohort of 479 patients who had been treated 
with Fowlers solution [potassium arsenite] for duration 
varying from 2 weeks to  12 years during the  period 
1945  – 1969.  The  median  cumulative  dose  in  this 
cohort was 448 mg. It was noted that in this cohort of 
patients there was a marginal increase in fatal and non-
fatal skin cancers but no increase in the incidence of 
internal malignancies.
39
A recent report that was meant to highlight the low 
probability of ATO having induced cancers in patients 
(3  cases)  receiving  oral  ATO
40 was  interpreted  in  a 
more recent review article as ‘highlights the concern of 
second malignancies’ in patients treated with ATO.
41
To the best of our knowledge there are no other (if one 
insists  on  considering  the  previous  report  as  second 
cancer  to  ATO  therapy)  reported  cases  of  second 
cancers  after  administration  of  ATO  at  currently 
defined therapeutic doses.  It would be reasonable at 
this  point,  though  with  limited  long  term  follow  up 
data, to state that second cancers following ATO are 
less  than  that  reported  following  therapy  of  acute 
myeloid leukemia with currently accepted standard of 
care regimens.  
There  have  been  concerns  raised  about  embryo 
toxicity based on animal models and some data from 
cases with environmental exposure.
42 This again is not Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
based on data in humans exposed to currently accepted 
therapeutic doses of ATO, this data for obvious ethical 
reasons is unlikely to be ever generated. However in 
our series, seven of the patients (4 women and 3 men) 
have had 8 normal babies,
15 though all happened after 
completion of therapy. In this relatively young cohort 
there were no reports of abortions, fetal abnormalities 
or still births in any couple. While we did not actively 
evaluate  fertility  there  were  no  reports  of  couples 
requesting evaluation for sterility.
15   
Hair and nail samples from 5 patients of this cohort 
who had completed therapy at least two years earlier 
was  compared  with  that  of  5  patients  who  had  just 
completed therapy (not from this cohort)  and 5 healthy 
controls.  There  was  no  significant  difference  in  the 
ATO retention in hair and nail samples of controls and 
patients who had completed therapy at least two years 
earlier.
15 The median levels, even among the patients 
who had just completed therapy was below the lower 
limit of the normal range described for normal controls 
by  the  Agency  for  Toxic  Substances  and  Disease 
Registry  (ATSDR  based  in  Atlanta,  Georgia,  USA 
(http://www.atsdr.cdc.gov/).
15        
Pattern  and  Timing  of  Haematopoietic  Recovery 
Following  Treatment  with  Single  Agent  Arsenic 
Trioxide.  In  our  initial  series  the  median  time  to 
achieve CR was  42  days  (range:  24-70).
16 However, 
this  figure  does  not  reflect  the  entire  details  of  the 
kinetics of leukemia clearance and pattern of normal 
hematopoiesis  recovery.  As  reported  initially  by  us 
about two thirds of patients have a leucocytic response 
after initiation of ATO while in about a third there is 
prolonged leucopenia prior to gradual normalization.
43
The  leucocytosis  can  at  times  be  very  rapid  and 
alarming and based on our early observations we had 
introduced  hydroxyurea  to  control  this  leucocytosis 
with a recommended sliding scale to adjust the dose 
depending on the WBC count.
16 We also noted that this 
was at times not adequate and we allowed use of an 
anthracycline in induction if there was rapid rise in the 
WBC counts after initiation of therapy at pre-defined 
levels  and  time  points.
16 In  cases  that  there  is 
leucocytic reponse there is often a second leucopenic 
phase (variable duration) and then recovery to normal 
values
43 (a triphasic response; Figure 3). Unlike with 
the  use  of  ATRA  plus  chemotherapy  schedules  the 
WBC count remains high (in two thirds) or very low 
(in one third), with a low platelet count and significant 
circulating  promyelocytes  for  the  first  two  weeks  as 
illustrated in Figure 4. At this time point  (around 2 
weeks  into  therapy)  there  is  often  a  concern  raised, 
among those not familiar with this agent, as to whether 
ATO  is  doing  anything  at  all  to  the  disease  and  a 
consideration to change protocol or add on additional 
drugs is discussed. However, if the diagnosis is correct, 
with  adequate  support  during  this  period  and 
continuing ATO, all patients will go on to achieve CR. 
Another  common  observation  in  some  cases  is  a 
clinically stable patient in the 4
th week of therapy, with 
a normal platelet count but very low WBC count and a 
consideration  to  stop  ATO  is  made  based  on  the 
argument that the ATO is causing a myelosuppresive 
effect. Our experience would suggest that ATO need 
not be stopped here but can be safely continued for the 
intended  duration  and  one  would  probably  be 
compromising  treatment  by  prematurely  stopping 
therapy at this time point.    
Figure 3. Average WBC count among patients with a leucocytic 
response and who achieved complete remission (n=6), illustrating 
the triphasic response.
Pattern of Molecular Response Following Therapy 
with Arsenic Trioxide. It is well recognized that the 
kinetics of leukemia clearance with the use of ATO, in 
induction, is significantly different from that of ATRA 
alone or ATRA plus chemotherapy combinations.
44 It 
is not well studied or reported as to what the effects of 
ATO  in  consolidation  and  maintenance  are  on  the 
kinetics  of  relapse.  Extrapolation  of  data  generated 
from  ATRA  plus  chemotherapy  regimens  may 
potentially not be valid when applied to regimens that 
use ATO in upfront therapy. With conventional ATRA 
plus chemotherapy regimens it is well recognized that a 
positive RT-PCR at the end of induction did not have a 
significant prognostic effect while in those who were 
positive  post  consolidation  had  an  increased  risk  of 
relapse.
41,45 From our own data (unpublished, accepted 
for presentation at ASH 2011) a positive RT-PCR at 
the end of induction was the most significant risk factor 
for subsequent risk of relapse on a multivariate analysis 
(RR=4.9;  95%  CI=1.13-21.20;  P-value=0.034)  and  a 
positive RT-PCR at this time point had a sensitivity of 
86.7% and specificity of 42.3% for predicting relapse 
(Figure  5).  In  this  single  agent  low  intensity  ATO 
regimen the presence of a positive RT-PCR at the end 
of induction could potentially help identify a subset of 
patients who may benefit from intensification of this Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 4. The mean WBC and Platelet count ± 1SE over time among patients treated on single agent ATO regimen. A)WBC response 
among those with leucocytosis (n=40). B) WBC response among those without leucocytosis (n=18). C) Platelet count recovery (n=60).
regimen.  This  strategy  remains  to  be  validated  in  a 
large clinical trial.   
Impact  of  Additional  Cytogenetic  and  Molecular 
Markers  Such  as  FLT3  Mutations  on  Clinical 
Response  Following  Treatment  with  Arsenic 
Trioxide. The presence of cytogenetic abnormalities at 
diagnosis remains an important prognostic variable in 
patients  with  newly  diagnosed  AML.
46 Secondary 
cytogenetic  changes  have  been  reported  to  have  an 
adverse  impact  in  some  subsets  of  AML,  though  in 
patients  with  APL  treated  with  conventional 
chemotherapy  a  similar  adverse  effect  was  not 
reported.
47,48 We  initially  reported  a  small  series  of 
newly diagnosed patients with APL treated with single 
agent ATO in which our analysis suggested that there 
was no significant adverse impact of the presence of an 
additional  karyotypic  abnormality  at  diagnosis
49. 
However,  a  more  recent analysis  of  our  data  (larger 
cohort)  does  suggest  that  there  may  be  an  adverse 
impact of an additional cytogenetic finding at diagnosis 
in  newly  diagnosed  patients  though  it  was  not 
significant  on  a  multivariate  analysis  (unpublished 
data).  
Fms-like tyrosine kinase 3 (FLT3) is a member of 
the  class  III  receptor  tyrosine  kinase  family  and  is 
expressed  on  haematopoietic  progenitors.
50,51
Mutations in the FLT3 receptors have been reported to 
be associated with a poor prognosis in both adult and 
paediatric patients with a diagnosis of acute myeloid 
leukaemia  (AML).
50 Mutations  in  the  FLT3  receptor 
are  commonly  seen  in  patients  with  APL
50.  The 
common  activating  mutations  of  FLT3  in  leukaemia 
include the FLT3 internal tandem duplication (FLT3-
ITD)  and  a  point  mutation  in  the  activation  loop 
(D835V).
50 A  recent  gene expression  profiling  study
reported  that  patients  with  APL  could  be  segregated 
into  those  with  and  without  a  FLT3-ITD  mutation, 
suggesting  that  these  groups  were  biologically 
different.
52  A retrospective analysis of the impact of 
FLT3  mutations  in  patients  with  APL,  treated  with 
conventional  ATRA  plus  chemotherapy  regimens, 
reported a higher incidence of induction deaths in one 
study
53 while another study reported a trend towards a 
shorter overall survival.
54 More recently Chillon et al
55
analyzed  the  Spanish  co-operative  group  data  and 
showed  that  ppatient’s  with  increased  ITD 
mutant/wild-type  ratio  or  longer  ITD  size  displayed 
shorter  5-year  relapse-free  survival  (RFS)  (P=0.048 
and  P<0.0001,  respectively),  though  patients  with 
D835  mutations did  not  show differences in  RFS or 
overall  survival  (OS).  In  our  series  we  found  that 
FLT3-ITD mutation in 21% and its presence did not 
impact  the  clinical  outcome  of  patients  treated  with 
ATO.
49 We  did  however  note  a  longer  time  to 
molecular  remission  among  those  who  were  FLT3 
mutation positive.
49
Figure 5. Event free survival and cumulative incidence of relapse 
based on RT-PCR positivity at the end of induction.
Arsenic  Trioxide  for  the  Treatment  of  Relapsed 
Acute Promyelocytic Leukemia. Patients who relapse 
following an ATRA based chemotherapy schedule can 
achieve  a  second  CR in  60  – 95%  of  cases  with 
chemotherapy though the toxicity with such a regimen 
in this population approaches that seen with high dose 
chemotherapy for acute myeloid leukemia.
36 There is a 
high incidence of ATRA resistance in this population 
especially  if  the  relapse  occurred  within  a  year  of 
completing an ATRA based chemotherapy schedule. In 
this  setting  ATO  is  extremely  effective  in  inducing Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
molecular  remissions  in  the  majority  of  patients 
without  the  toxicity  profile  of  combination 
chemotherapy and does not have cross resistance with 
ATRA.
36 This  is  the  only  indication  for  which  it  is 
approved  by  the  United  States  Food  &  Drug 
Administration (FDA). Achieving molecular remission 
prior to a consolidation with an autologous stem cell 
transplant,  the  preferred  option  in  this  setting,  has  a 
significant bearing on long term outcome. Use of single 
agent  ATO  as  consolidation  therapy  after  achieving 
molecular  remission  was  less  effective  in  this 
population with a 2 year OS of 41% in one series
36 and 
an EFS of 33% in a second.
37 In our own series we 
reported  a  significantly  better  clinical  outcome  in 
patients  who  were  consolidated  with  an  autologous 
SCT  versus  those  consolidated  with  ATO  or 
ATO+ATRA  following  treatment  of  a  frank 
hematological relapse of APL.
56 Based on the available 
data  it  would  be  reasonable  in  patients  with  a 
hematological  relapse  to  induce  molecular  remission 
with  ATO  and  consolidate  with  an  autologous  SCT 
(SCT) in those who achieve molecular remission and 
consider  an  allogeneic  SCT  for  those  who  fail  to 
achieve a molecular remission. 
Conclusions. While there is no doubt as to the efficacy 
of ATO in the management of APL, its position in the 
algorithm  in  the  treatment  of  this  condition  is  still 
being defined for newly diagnosed cases. Based on the 
available data, it is clear that as a single agent it is the 
most effective drug in the management of APL. For 
patients  who  have  relapsed  following  conventional 
ATRA  plus  chemotherapy  regimens  it  is  the 
established  agent  of  choice  to  induce  a  second 
molecular  remission.  Preliminary  concerns  of  fatal 
toxicity  profile  appear  to  be  related  more  to  the 
associated co-morbid conditions than the drug itself, as 
noted  by  their  absence  when  used  in  patients  with 
newly  diagnosed  APL  without  co-morbid  conditions 
and in other malignant conditions. On going concerns 
that  are  frequently  voiced  about  potential  long  term 
toxicity  are  not  based  on  significant  data.  Better 
understanding  of  its  in-vivo  biotransformation  and 
effect of the different methylated derivatives that are 
generated in this process, could potentially help further 
reduce its toxicity profile while enhancing its efficacy. 
This  could  be  achieved  by  better  ability  to  predict 
toxicity  or  efficacy  based  on  genetic  polymorphisms 
that have an impact on biotransformation pathways or 
by  the  use  of  specific  methylated  derivatives  for 
therapy rather than the native compound which further 
research may potentially demonstrate to have a more 
favorable therapeutic profile. 
In  the  developing  world  where  the  cost  of  ATO 
(generic)  is  low,  the  absence  of  grade  III/IV 
neutropenia  and  mucositis  along  with  the  ability  to 
administer the regimen on an out  patients basis post 
remission  induction  significantly  reduces  the  cost  of 
treating  this  condition  in  comparison  to  a  standard 
ATRA plus chemotherapy regimen. In summary there 
is sufficient evidence to embrace ATO as an important 
drug in the armamentarium for the treatment of APL, 
the  optimal  mode,  combination  and  schedule  for 
utilization  of  this  agent  in  newly  diagnosed  cases 
remains to be defined. 
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